Citigroup
FRTX

Citigroup’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Citigroup’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,796
Closed -$10K – 6492
2022
Q2 		$10K Buy
+1,796
New +$16.3K ﹤0.01% 5378
2019
Q4 		– Sell
-1
Closed – – 7846
2019
Q3 		$0 Hold
1
– – ﹤0.01% 7855
2019
Q2 		$0 Hold
1
– – ﹤0.01% 7886
2019
Q1 		$0 Hold
1
– – ﹤0.01% 7861
2018
Q4 		$0 Hold
1
– – ﹤0.01% 7878
2018
Q3 		$0 Hold
1
– – ﹤0.01% 7907
2018
Q2 		$0 Hold
1
– – ﹤0.01% 7782
2018
Q1 		$0 Hold
1
– – ﹤0.01% 7711
2017
Q4 		$0 Hold
1
– – ﹤0.01% 7685
2017
Q3 		$0 Hold
1
– – ﹤0.01% 7503
2017
Q2 		$1K Sell
1
-5
-83% -$3.66K ﹤0.01% 7234
2017
Q1 		$4K Hold
6
– – ﹤0.01% 6877
2016
Q4 		$4K Hold
6
– – ﹤0.01% 6988
2016
Q3 		$5K Hold
6
– – ﹤0.01% 6790
2016
Q2 		$8K Sell
6
-17
-74% -$21.9K ﹤0.01% 6652
2016
Q1 		$28K Buy
23
+3
+15% +$3.46K ﹤0.01% 6400
2015
Q4 		$26K Buy
20
+5
+33% +$6.52K ﹤0.01% 6356
2015
Q3 		$21K Sell
15
-2
-12% -$3.86K ﹤0.01% 6010
2015
Q2 		$38K Sell
17
-8
-32% -$25.1K ﹤0.01% 5721
2015
Q1 		$73K Buy
25
+7
+39% +$22.4K ﹤0.01% 5263
2014
Q4 		$61K Sell
18
-2
-10% -$7.08K ﹤0.01% 5564
2014
Q3 		$71K Buy
20
+1
+5% +$3.89K ﹤0.01% 5046
2014
Q2 		$75K Sell
19
-5
-21% -$18.8K ﹤0.01% 4880
2014
Q1 		$96K Buy
24
+1
+4% +$4.46K ﹤0.01% 5032
2013
Q4 		$87K Buy
23
+15
+188% +$56.8K ﹤0.01% 5351
2013
Q3 		$31K Buy
8
+2
+33% +$15K ﹤0.01% 5622
2013
Q2 		$60K Buy
+6
New +$66.5K ﹤0.01% 5252

Other funds holding FRTX

TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup's FRTX Position: Q3 2022 in Review

Citigroup sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2022, closing a stake of 1,796 shares — an estimated $10K sold.

Citigroup first reported a position in FRTX in Q2 2013 and held it in 27 quarters. The position peaked at $96K in Q1 2014. 17 funds tracked by Wall St. Rank hold FRTX as of Q3 2022.

  • Citigroup reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 1,796 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $10K.
  • Citigroup first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
  • Citigroup's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $96K in Q1 2014.
  • 17 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.